Breakthrough in SCN2A Treatment: Promising Results from the EMBOLD Study on Relutrigin (Prax-562) Offer New Hope for Patients and Families
Kris Pierce (GAICD)
Director | Lived Experience & Engagement Strategist | Rare disease | Rare Epilepsy | Health Research | Victorian Honour Roll for Women Inductee
Recent findings from the EMBOLD study on Relutrigin (Prax-562) offer encouraging news for the SCN2A community. The study has demonstrated notable potential in treating Developmental and Epileptic Encephalopathies (DEE), particularly in individuals with SCN2A and SCN8A-related conditions. These results provide a positive outlook for patients and families managing these complex conditions.
Key Findings from the Study
The EMBOLD study has produced several important results that underscore the potential benefits of Relutrigin for patients with DEE:
Looking Ahead
Building on the promising outcomes of the EMBOLD study, several next steps are planned:
A Positive Outlook for the SCN2A Community
The EMBOLD study represents a positive step forward in the treatment of DEE, offering potential benefits in seizure control and overall patient well-being. As we move into the next phases of research and regulatory processes, there is cautious optimism that Relutrigin could become a valuable treatment option for the SCN2A community.
These findings bring us closer to a future where patients and families affected by SCN2A and similar conditions may see improvements in their quality of life. The journey continues, with hope that ongoing research and development will lead to effective and accessible treatments.
More information here